GPs begin prescribing Mounjaro weight-loss jabs in England

GP surgeries in England start prescribing Mounjaro today, but only patients with severe obesity and multiple health conditions will qualify under strict eligibility rules.

The weekly injection, which helps suppress appetite to support weight loss of up to 20 per cent of body weight, is being rolled out in phases by NHS England.

The approach is designed to manage demand and prioritise those most in need, while easing pressure on GP workloads.

To be eligible in the initial stage, patients must have a body mass index (BMI) – a measure comparing weight to height – of 40 or above (37.5 for those from minority ethnic backgrounds), and also be living with at least four of the following conditions: type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol, and obstructive sleep apnoea, a disorder that causes breathing to stop and start during sleep.

Dr Claire Fuller, co-national medical director of primary care at NHS England, said: “This is an important next step in the rollout of weight-loss drugs, with community-based services now able to offer this treatment from today.”

Patients who qualify will be supported with regular health reviews, tailored physical activity plans and dietary guidance.

However, not all GP surgeries will prescribe the jab directly – in some areas, it will be offered through other parts of the primary care system. NHS England advises people to check their integrated care board’s website for local information.

The Royal College of General Practitioners has warned that the new demand could strain already overstretched services.

Professor Kamila Hawthorne, its chair, said the treatment can be effective, but GPs are “over-burdened” and do not have the workforce needed.

She said: “It’s a lot safer to come to us than buying online or over the counter, but we are asking people not to approach GPs unless they think they meet the criteria.”

Some practices have issued notices saying few patients will initially qualify, and others are asking for patience while community services are established.

Malcolm Harrison, chief executive of the Company Chemists’ Association, said the new treatment has the potential to “transform the lives” of many, but added: “It is unlikely that the planned GP provision will be sufficient to meet patient demand.”

Also known as tirzepatide, the medicine was originally approved to treat type 2 diabetes and later licensed for weight management.

Monthly check-ups are required during the first months of treatment.

It is not suitable for pregnant or breastfeeding women, those trying to conceive, or individuals with conditions such as pancreatitis or certain thyroid tumours.

Around 220,000 people are expected to receive Mounjaro in the initial phase. Over the next 12 years, an estimated 3.4m people may become eligible.

The National Institute for Health and Care Excellence (NICE) will assess progress before any wider expansion.